Across clinical studies, regimens with EMEND or EMEND for Injection
were generally well tolerated
The overall safety profile of EMEND was evaluated in approximately 3,800 patients.
Most common clinical adverse events — moderately emetogenic chemotherapy
Most common clinical adverse events — highly emetogenic chemotherapy
Selected Important Risk Information
The most frequent clinical adverse events reported in patients receiving EMEND for Injection were infusion site pain (7.6%), headache (3.0%), and infusion site induration (1.5%).
There have been isolated reports of immediate hypersensitivity reactions including flushing, erythema, and dyspnea during infusion of fosaprepitant. These reactions have generally receded when the infusion was stopped and appropriate therapy was provided. It is not recommended to reinitiate the infusion in patients who have these reactions.
PRIVACY POLICY